Hanmi Pharm secures top ESG rating for second year.
Samsung Biologics showcases CDO platforms at PEGS Boston.
Daewoong Pharma inks deal for novel IBD drug candidate.
Composite illustration of Korean pharma ESG, IBD therapy, PEGS expo and smart hospital tech. Generated with ChatGPT.
Hanmi Pharm was included in the Dow Jones Best-in-Class Korea Index for the second straight year. The recognition covers its carbon-neutral governance, preventive safety systems, and access programs for medicines in the least developed countries. A company official said the firm will refine its ESG framework to meet global standards.
Daewoong Pharma signed a licensing agreement with Innovotherapeutics for INV-008, a 15-PGDH inhibitor for the treatment of inflammatory bowel disease. The oral candidate promotes mucosal healing in ulcerative colitis and Crohn's disease. The agreement totals 662.5 billion won, including upfront payments and milestones.
Samsung Biologics presented at the 2026 PEGS Boston summit from May 11 to 15. The firm highlighted its organoid technology and DEVELOPICK platform for oncology drug development during a lunch session. It operates nine CDO platforms to support clients from early discovery to IND filing.
Dong-A ST supplied AI-smart hospital solutions for 236 beds at Chonnam National University Hospital. The systems include HiCardi Plus for vital sign monitoring and Live Studio X for central control. The setup aims to improve patient safety and staff efficiency in key departments.
These moves reflect Korean biopharma's push into sustainable practices, innovative therapies, and digital health amid global demand for advanced solutions.
By Min Byung-kwun, KDFN
kdf＠kdfnews.com
댓글
0